PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March.
| Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023) | |
| Format: | Tumor Diagnostic Development Corporate Panel |
| Date: | Wednesday, March 8, 2023 |
| Time: | 9:10 – 10:20 AM ET |
| Oppenheimer’s 33rd Annual Healthcare Conference (March 13-15, 2023) | |
| Format: | Fireside Chat |
| Date: | Monday, March 13, 2023 |
| Time: | 8 AM ET |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Contacts
Investor Contact:
Winston Kung
PMV Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Kathy Vincent
Greig Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.67 |
| Daily Change: | -0.03 -1.48 |
| Daily Volume: | 85,279 |
| Market Cap: | US$86.160M |
November 07, 2024 August 08, 2024 May 09, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
